SELLAS Life Sciences Group, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.0M | $7.6M | $1.9M | $0 |
| Cost of Revenue | — | $0 | $0 | $0 | $100.0K | $200.0K | $0 | — |
| Gross Profit | — | — | — | $0 | $900.0K | $7.4M | $1.9M | — |
| Gross Margin | — | — | — | — | 90.0% | 97.4% | 100.0% | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | $15.7M | $9.3M | $7.3M |
| SG&A Expense | — | $12.3M | $12.4M | $13.9M | $12.6M | $11.3M | $9.6M | $9.9M |
| Operating Income | — | $-28.3M | $-31.5M | $-37.9M | $-42.0M | $-25.3M | $-17.0M | $-20.0M |
| Operating Margin | — | — | — | — | -4,195.0% | -332.8% | -893.8% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-26.9M | $-30.9M | $-37.3M | $-41.3M | $-20.9M | $-16.8M | $-19.4M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K |
| Net Income | — | $-26.9M | $-30.9M | $-37.3M | $-41.3M | $-20.7M | $-16.8M | $-19.3M |
| Net Margin | — | — | — | — | -4,130.1% | -272.4% | -881.9% | — |
| EPS (Basic) | — | $-0.25 | $-0.50 | $-0.67 | $-1.07 | $-0.67 | $-1.06 | $-5.46 |
| EPS (Diluted) | — | $-0.25 | $-0.50 | $-0.67 | $-1.07 | $-0.67 | $-1.06 | $-5.46 |
| Shares Outstanding (Basic) | 179.6M | 109.1M | 61.2M | 55.6M | 38.8M | 31.0M | 16.0M | 10.2M |
| Shares Outstanding (Diluted) | 179.6M | 109.1M | 61.2M | 55.6M | 38.8M | 31.0M | 16.0M | 10.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |